Ibex Biosciences has a robust pipeline of unique pre-clinical programs consisting of Antibodies, Regeneration and Gene Therapies as summarized below:
Ibex is currently involved in pre-clinical therapeutic antibody programs targeted towards Malaria and Oncology. Moreover, we are characterizing these antibodies for potential use in the treatment of various inflammatory conditions.
In addition, Ibex has successfully developed a polyclonal for the immunohistochemistry (IHC) diagnostics of cervical intraepithelial neoplasia (CIN) and skin lesions.
Ibex is in the process of validating its unique regenerative platform. This platform operates similarly to reprogramming but seeks to utilize gene therapy to facilitate the functional repair of damaged cells In-situ.
Ibex holds a patent related to the use of its transcription factor, aimed at fostering regeneration while inhibiting oncogenesis.
Ibex is actively pursuing several pre-clinical gene therapy programs, with a primary focus on direct targeting of cancerous tumors and mitigating both chronic and acute inflammation.
These programs leverage a diverse range of novel Adeno-associated virus (AAV) serotypes and promoters, enhancing the precision of specific tissue targeting. This strategy aims to optimize the delivery and efficacy of our gene therapies.